QPPV.COM KNOWLEDGE ASSESSMENT

Periodic Benefit-Risk Evaluation Reports (PBRER) Knowledge Assessment

Test your understanding of the concepts covered by Periodic Benefit-Risk Evaluation Reports (PBRER).

Question 1 of 10Pass mark: 80%

Question 1 of 10 What should determine the strength of language used in a PBRER conclusion?

The commercial importance of the medicinal product The length of the report The strength and limitations of the supporting evidence The number of reviewers who agree with the draft

Question 2 of 10 Which group of activities should be considered when preparing for a forthcoming DLP?

Only reconciliation of the spontaneous reporting database Only formatting and document conversion activities The status of signal evaluations, studies, regulatory procedures, reference safety information and data readiness Only activities that have already resulted in a product information change

Question 3 of 10 Why is a PBRER not equivalent to an expanded line listing?

Because a PBRER excludes spontaneous reports entirely Because a PBRER focuses on prospective risk planning rather than post-authorisation evidence Because a PBRER interprets cumulative evidence and its implications for benefit-risk, rather than merely displaying cases Because a PBRER contains only efficacy information

Question 4 of 10 Which practice best reduces confirmation bias during aggregate medical review?

Treating previous conclusions as the default interpretation of all new data Actively looking for evidence that contradicts prior conclusions and considering alternative explanations Focusing only on findings that are statistically significant Avoiding discussion of uncertainty to preserve confidence in the report

Question 5 of 10 What is the most accurate operational meaning of the Data Lock Point?

The date on which the competent authority completes its assessment The date after which no new pharmacovigilance activity may occur The cut-off date defining which information belongs in the current periodic report The date on which the marketing authorisation holder must submit the final document

Question 6 of 10 What is the most appropriate role of risk management plan information in a PBRER?

To reproduce the entire Risk Management Plan without interpretation To provide context on monitored risks and missing information and contribute relevant findings to the integrated assessment To replace the assessment of spontaneous reports and clinical studies To demonstrate that no further benefit-risk evaluation is needed

Question 7 of 10 Why must the clinical context of a serious adverse reaction be considered during benefit-risk evaluation?

The same adverse reaction can have different implications depending on disease severity, therapeutic benefit and available alternatives Serious reactions are excluded from benefit-risk assessment when treatment is effective Clinical context determines whether an individual case is legally reportable but has no relevance to aggregate review A serious reaction always outweighs any therapeutic benefit

Question 8 of 10 A company plans to begin scientific review only on the day the report is submitted. Which concept from the article shows why this plan is inadequate?

The Data Lock Point is the submission date The report requires substantial post-DLP activities such as validation, medical review, writing, quality control and approval The PSUSA procedure begins only after the company has completed submission The QPPV is required to personally author every section before the DLP

Question 9 of 10 Which division of responsibility between legislation and pharmacovigilance guidance is most accurate?

GVP establishes the legal reporting obligation, while legislation provides optional scientific recommendations ICH guidelines create legally binding EU submission duties, while legislation addresses only clinical trials EU legislation establishes legal obligations, while GVP provides detailed implementation guidance The EURD List replaces both legislation and GVP for periodic reporting purposes

Question 10 of 10 A potential risk remains incompletely characterised after the reporting interval, but available evidence does not demonstrate a change in the overall benefit-risk balance. Which conclusion is most consistent with the article?

The uncertainty should be concealed because the balance remains favourable The potential risk should automatically be declared an identified risk The uncertainty should be described accurately, its clinical significance assessed and any need for further monitoring explained The product should automatically be withdrawn

Periodic Benefit-Risk Evaluation Reports (PBRER) Knowledge Assessment

Cookie Settings